Streetbeat News

Analyst Ratings

PSTG

UBS analyst David Vogt maintains a Neutral rating on Pure Storage (NYSE:PSTG) and raises the price target from $31 to $38.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 1:29 pm

CRM

UBS analyst Karl Keirstead maintains a Neutral rating on Salesforce (NYSE:CRM) and raises the price target from $220 to $240.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 1:28 pm

JNJ

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Johnson & Johnson (NYSE:JNJ) and maintained a price target of $215.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 1:26 pm

ROIV

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Roivant Sciences (NASDAQ:ROIV) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 1:25 pm

CHMI

B. Riley Securities analyst Matt Howlett maintains a 'Buy' rating on Cherry Hill Mortgage (NYSE:CHMI) but lowers the price target from $6 to $5.5.

Portfolio Pulse from Benzinga Newsdesk

August 31, 2023 | 1:25 pm

EYPT

Cantor Fitzgerald analyst Jennifer Kim has reiterated her Overweight rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and maintained a price target of $31.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 1:25 pm

OKTA

DA Davidson analyst Rudy Kessinger maintains a Neutral rating on Okta (NASDAQ:OKTA) and raises the price target from $75 to $80.

Portfolio Pulse from Benzinga Newsdesk

August 31, 2023 | 1:24 pm

DNLI

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a price target of $85.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 1:23 pm

FIVE

Craig-Hallum analyst Jeremy Hamblin maintains a 'Buy' rating on Five Below (NASDAQ:FIVE) but lowers the price target from $224 to $215.

Portfolio Pulse from Benzinga Newsdesk

August 31, 2023 | 1:23 pm

PRTG

Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Portage Biotech (NASDAQ:PRTG) and maintained a price target of $11.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 1:23 pm